Immunocore Holdings (IMCR) Common Equity (2019 - 2026)

Immunocore Holdings has reported Common Equity for 8 years, with the latest figure at $393.7 million in Q1 2026.

• Quarterly Common Equity rose 4.01% year-over-year to $393.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $393.7 million (up 4.01% YoY) and the FY2025 annual result came in at $381.0 million, up 5.63% from the prior year.
• Common Equity improved to $393.7 million in Q1 2026 per IMCR's latest filing, from $381.0 million in the prior quarter.
• Over five years, Common Equity peaked at $396.6 million in Q3 2025 and troughed at $207.3 million in Q2 2022.
• A 5-year average of $355.9 million and a median of $360.1 million in 2024 frame the typical range for Common Equity.
• The sharpest annual moves came in 2023 and 2024: Common Equity soared 69.49% in 2023, then retreated 2.2% in 2024.
• Over 5 years, Common Equity stood at $327.0 million in 2022, then rose by 12.81% to $368.8 million in 2023, then declined by 2.2% to $360.7 million in 2024, then climbed by 5.63% to $381.0 million in 2025, then gained by 3.32% to $393.7 million in 2026.
• According to Business Quant data, Common Equity over the past three periods registered $393.7 million, $381.0 million, and $396.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.